within Pharmacolibrary.Drugs.G_GenitoUrinarySystemAndSexHormones.G03A_HormonalContraceptivesForSystemicUse.G03AB09_NorgestimateAndEthinylestradiol;

model NorgestimateAndEthinylestradiol
  extends Pharmacolibrary.Drugs.ATC.G.G03AB09;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>G03AB09</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Norgestimate and ethinylestradiol is a combined oral contraceptive used for the prevention of pregnancy. It contains norgestimate, a progestin, and ethinylestradiol, a synthetic estrogen. This combination is widely approved and currently used for contraception, regulation of menstrual cycles, management of acne, and other hormonal indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters refer to healthy adult women of reproductive age, following oral administration of a single combined tablet containing 0.25 mg norgestimate (as the total) and 0.035 mg ethinylestradiol.</p><h4>References</h4><ol><li><p>Song, IH, et al., &amp; Piscitelli, SC (2015). Dolutegravir Has No Effect on the Pharmacokinetics of Oral Contraceptives With Norgestimate and Ethinyl Estradiol. <i>The Annals of pharmacotherapy</i> 49(7) 784–789. DOI:<a href=\"https://doi.org/10.1177/1060028015580637\">10.1177/1060028015580637</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25862012/\">https://pubmed.ncbi.nlm.nih.gov/25862012</a></p></li><li><p>Bifano, M, et al., &amp; Bertz, R (2014). Effect of the coadministration of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate. <i>Antiviral therapy</i> 19(5) 511–519. DOI:<a href=\"https://doi.org/10.3851/IMP2718\">10.3851/IMP2718</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24343001/\">https://pubmed.ncbi.nlm.nih.gov/24343001</a></p></li><li><p>Schmitt-Hoffmann, AH, et al., &amp; Maares, J (2011). Influence of alitretinoin on the pharmacokinetics of the oral contraceptive ethinyl estradiol/norgestimate. <i>Clinical and experimental dermatology</i> 36 Suppl 2 4–11. DOI:<a href=\"https://doi.org/10.1111/j.1365-2230.2011.04031.x\">10.1111/j.1365-2230.2011.04031.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21443598/\">https://pubmed.ncbi.nlm.nih.gov/21443598</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end NorgestimateAndEthinylestradiol;
